Hematology/Oncology

Top Story

VIDEO: Highlights from the 2017 HemOnc Today Melanoma and Cutaneous Malignancies meeting

March 26, 2017

NEW YORK — Sanjiv S. Agarwala, MD, professor of medicine at Temple University School of Medicine, chief of hematology and oncology at St. Luke’s Cancer Center, and a HemOnc Today Editorial Board member, discussed highlights from HemOnc Today Melanoma and Cutaneous Malignancies.

Meeting NewsVideo

VIDEO: New immune targets may improve advanced melanoma outcomes

March 25, 2017
NEW YORK — Michael A. Postow, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discussed new immunotherapy targets for advanced melanoma beyond…
Meeting News

Anti–PD-1/PD-L1 therapy ‘rapidly becoming’ standard of care for Merkel cell carcinoma

March 25, 2017
NEW YORK — Immunosuppressive therapies, including anti–PD-1/PD-L1 agents, have led to durable responses among patients with Merkel cell carcinoma. However…
Meeting News

Challenges remain in determining appropriate sequence of immunotherapy, BRAF/MEK inhibition

March 25, 2017
NEW YORK — The optimal sequence of immunotherapy and BRAF/MEK inhibition for the first-line treatment of melanoma has only been evaluated retrospectively and…
Meeting News

Hedgehog inhibitors ‘game changers’ for advanced basal cell carcinoma

March 25, 2017
NEW YORK — Hedgehog inhibitors have demonstrated high efficacy and durability for patients with advanced basal cell carcinoma, according to a speaker at HemOnc
More News Headlines »
CME

Hot Topics in Metastatic Breast Cancer Management: Clinical Advances with CDK4/6 Inhibitors

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

While the mortality rates for advanced or metastatic breast cancer (MBC) have steadily decreased, in part due to…
More »
Video
Meeting News

VIDEO: Resurgence of cutaneous radiation therapy for skin cancer

March 21, 2017
More »
Featured
HEMONC TODAY Melanoma and Cutaneous Malignancies

HEMONC TODAY Melanoma and Cutaneous Malignancies

CME

Immuno-Oncology Forum: Focus on Non-Small Cell Lung Cancer

This activity is supported by educational grants from Bristol-Myers Squibb; Genentech, Inc.; and Merck & Co., Inc.

Lung cancer accounts for 27% of all cancer deaths in the United States, making it the leading cause of cancer…
More »
Current Issues
View the Current Issue
HemOnc Today
Advertisement
Advertisement